



## Company Fact Sheet

### Corporate Overview

Based in Longmont, Colorado, privately-held MicroPhage, Inc. develops rapid, easy-to-use diagnostic products for bacterial identification and antibiotic susceptibility/resistance testing using its proprietary Bacteriophage Amplification Technology (BAT™) platform. The MicroPhage test platform does not require any instrumentation and is simple to operate, enabling time-critical microbiology testing in healthcare facilities of any size or financial means.

### Product Overview

MicroPhage's first product, the MicroPhage KeyPath™ MRSA/MSSA Blood Culture Test – BT, simultaneously identifies *Staphylococcus aureus* bacteria and determines if the strain is methicillin resistant (MRSA) or methicillin susceptible (MSSA), and returns these results within one day.

The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the KeyPath™ MRSA/MSSA Blood Culture Test – BT in May 2011. The test obtained CE Mark in Europe in 2009.

### Product Pipeline

MicroPhage's pipeline includes KeyPath™ tests and MicroPhAST™ test panels delivering bacterial identification and susceptibility for:

- Gram-positive bacteria in positive blood cultures
- Gram-negative bacteria in positive blood cultures
- *Escherichia coli* (*E. coli*) in urinary tract infections (UTI)
- Skin and soft tissue infections (SSTI or SSI) in wound specimens
- Respiratory infections (pneumonia) in respiratory samples
- Individual drug susceptibility tests and panels for key breakpoint determinations

### Management Team

- Don Mooney, President & CEO
- J. Drew Smith, Ph.D., Chief Science Officer
- Brian MacDonald, Vice President, Sales and Marketing
- Preston Brown, Manufacturing Director
- Michelle Dowling, Quality Director

### Corporate Headquarters

2400 Trade Centre Avenue  
Longmont, CO 80503

Phone: 303.652.5200

Website: [www.microphage.com](http://www.microphage.com)

MicroPhage has 18 employees.

#### **Board of Directors**

- **R. Gary Mesch** – Chairman of the Board; Managing Director, Alpine Angels
- **Don Mooney** – President & CEO, MicroPhage
- **Larry Gold, Ph.D.**, – Founder and Chairman of SomaLogic, Inc.
- **Rick Norling** – Director
- **Mel Schatz** – Director; President & CEO, Crux Biomedical
- **Mark Schwartz, M.D., J.D.** – Director
- **Lynn M. Taussig, M.D.** – Director

#### **Investors**

The company was founded in 2002 and has been funded by angel investors. Since inception, the company has received over \$19 million in angel investments.

###